COVID-19 Information

In these unprecedented times, Novartis is here to help

At Novartis, we are committed to patient health and well-being and are closely monitoring the coronavirus disease 2019 (COVID-19) situation. It’s important that you take precautions to reduce the risk of contracting COVID-19. Contact your prescribing health care provider if you have any questions or concerns about your treatment with nonimmunosuppressive PROMACTA® (eltrombopag) when considering whether you should receive any vaccine.


If you have persistent or chronic immune thrombocytopenia (ITP) and have failed to respond to at least 1 ITP treatment, ask your doctor about nonimmunosuppressive PROMACTA.


Additional resources to stay informed—and involved

Below are helpful links that may help answer some of your questions, including information from the Platelet Disorder Support Association (PDSA) and the American Society of Hematology (ASH). We encourage you to engage in shared decision making with your doctor to ensure that your treatment and care meet your needs.


PDSA: Frequently asked questions (COVID-19 and ITP)


ASH: Information updates (COVID-19 and ITP)


Novartis response to COVID-19

novartis_logo.jpgThe Novartis COVID-19 Response Fund is providing urgently needed support for health care workers and communities in more than 50 projects around the world. Novartis established a $20 million global fund in mid-March 2020 to support communities around the world impacted by the COVID-19 pandemic. The fund aims to support public health initiatives designed to help communities manage the challenges posed by the pandemic, such as programs to strengthen health care infrastructure, digital platforms for data collection or dissemination of important public health information, and community health programs.


To learn more about how Novartis is responding to COVID-19, visit


Our Customer Interaction Center can also be reached by phone at: 1-888-NOW-NOVA (1-888-669-6682) Monday through Friday, 8:30 AM to 5:00 PM ET.